Drug intelligence / Profile preview

paclitaxel + isotretinoin + interferon alfa-2b

Development stage: Unknown
Lead developer: University of Medicine and Dentistry of New Jersey
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Subcutaneous, Intravenous

Overview

A combination chemotherapy regimen consisting of the taxane paclitaxel, the retinoid isotretinoin (13-cis retinoic acid), and the biologic immunomodulator interferon alfa-2b. Developed and studied by the University of Medicine and Dentistry of New Jersey (now Rutgers New Jersey Medical School), this regimen was evaluated in a Phase II clinical trial for the treatment of advanced, recurrent, or persistent cervical cancer. The therapeutic rationale behind the combination is chemosensitization; isotretinoin and interferon alfa-2b are used to synergistically downregulate the anti-apoptotic protein bcl-2, thereby overcoming drug resistance and enhancing the cytotoxic efficacy of paclitaxel-mediated microtubule stabilization.

Other names: paclitaxel-University of Medicine and Dentistry of New Jersey-cervical cancerChemosensitization with Paclitaxel, Isotretinoin, and Interferon Alpha-2bPaclitaxel, 13-cis Retinoic Acid and Interferon Alpha-2b combination

Targets

TUBB (Tubulin (alpha and beta subunits))IFNAR1 (Interferon alpha/beta receptor 1)RAR (Retinoic acid receptor)

Beyond the preview

Go deeper on paclitaxel + isotretinoin + interferon alfa-2b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + isotretinoin + interferon alfa-2b.

Explore the full profile